Pasadena, CA, United States of America

Skylar K Osler

This inventor holds 1 USPTO granted patent. Top assignee: Merck Sharp & Dohme LLC. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 15.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Skylar K Osler: Innovator in Plasma Kallikrein Inhibitors

Introduction

Skylar K Osler is a notable inventor based in Pasadena, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of plasma kallikrein inhibitors. His work focuses on creating compounds that can effectively treat various disease states.

Latest Patents

Skylar holds 1 patent for his invention related to plasma kallikrein inhibitors. The patent describes a compound of Formula (I) and pharmaceutical compositions that include one or more of these compounds. These compounds are designed to treat or prevent conditions such as hereditary angioedema, uveitis, posterior uveitis, wet age-related macular edema, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. The compounds are recognized as selective inhibitors of plasma kallikrein.

Career Highlights

Skylar is currently employed at Merck Sharp & Dohme LLC, where he continues to advance his research and development efforts. His work has the potential to significantly impact the treatment of various eye and blood-related conditions.

Collaborations

Skylar collaborates with talented individuals in his field, including Rohan Rajiv Merchant and Ying-Duo Gao, who is a woman. Their combined expertise contributes to the innovative research being conducted at Merck Sharp & Dohme LLC.

Conclusion

Skylar K Osler is a dedicated inventor whose work in plasma kallikrein inhibitors showcases his commitment to advancing medical science. His contributions are paving the way for new treatments that could benefit many patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…